Natera, Inc. (NTRA) News
Track canonical SquawkNews coverage tagged to NTRA, Natera, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 27 indexed stories across 19 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Natera Q1 revenue jumps; raises FY guidance; MRD patents upheld
Natera reported Q1 2026 revenue of $696.6M, raised full-year guidance to $2.74B–$2.82B, and won a court ruling upholding three MRD patents tied to a 30% ongoing royalty and preserved damages vs. Invitae. The update also
EQUITY | Sep 21, 2026, 11:28 AM UTC
L
NTRA - Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
NTRA - Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
NEWS | Sep 18, 2026, 10:09 AM UTC
M
Natera reports WCLC dataset of Signatera MRD in NSCLC
Natera announced WCLC data from 1,129 resected stage 1-3 NSCLC patients, saying Signatera MRD status predicts recurrence-free and overall survival in early post-surgical and surveillance settings.
EQUITY | Sep 18, 2026, 10:00 AM UTC
L
UBS raises Natera price target to $435
UBS raised Natera’s price target to $435.00 per share from $290.00 and maintained a Buy rating.
EQUITY | Sep 09, 2026, 06:04 PM UTC
L
Natera initiated at Buy by Rothschild & Co
Rothschild & Co initiated coverage on Natera with a Buy rating.
EQUITY | Sep 08, 2026, 12:32 PM UTC
L
NTRA publication cites strong clinical validation for Signatera MRD in lymphoma
TradeXchange Newsdesk says NTRA published findings supporting Signatera for MRD assessment in lymphoma.
EQUITY | Sep 01, 2026, 10:05 AM UTC
L
Natera publishes new clinical validation of Signatera for lymphoma MRD
Natera said new data published in Blood Neoplasia validates the prognostic and predictive value of Signatera for MRD assessment in newly diagnosed and relapsed/refractory lymphoma patients.
EQUITY | Sep 01, 2026, 10:00 AM UTC
L
Natera and Susan G. Komen announce national breast cancer partnership
Natera and Susan G. Komen® announced a national partnership to accelerate progress against breast cancer.
EQUITY | Aug 28, 2026, 03:06 PM UTC
L
Natera partners with Angiex for ctDNA monitoring in solid tumor trial
Natera partnered with Angiex to support ctDNA monitoring in a solid tumor trial using Signatera.
EQUITY | Aug 27, 2026, 11:11 AM UTC
L
Natera and Angiex partner to assess nuclear-delivered ADC with Signatera
Natera and Angiex will assess response to an investigational nuclear-delivered antibody-drug conjugate using Signatera.
EQUITY | Aug 27, 2026, 10:00 AM UTC
L
Natera Supports Clinical Trial
Natera is supporting a clinical trial assessing ctDNA dynamics with Latitude in advanced skin cancers
EQUITY | Aug 12, 2026, 10:02 AM UTC
H
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Friday. Shares of Natera Inc (NASDAQ: NTRA ) rose sharply after the company reported better-than-expected quarterly financial results and raised its
EARNINGS | Aug 07, 2026, 07:35 PM UTC
L
Natera CEO Says Company Is 'Clearly on a Roll' After Record Test Volumes, Raises Outlook
Natera Inc. (NASDAQ: NTRA ) stock surged Friday after the genetic testing company reported second-quarter results that topped Wall Street estimates and raised its full-year revenue outlook, supported by strong oncology d
EARNINGS | Aug 07, 2026, 06:35 PM UTC
H
JS&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today
The S&P 500 cleared 7,755 and Wall Street is on course for its best week since April. The rally comes on the heels of a contraction in July payrolls. The U.S. economy unexpectedly shed 23,000 jobs in July against forecas
EARNINGS | Aug 07, 2026, 05:27 PM UTC
L
Natera Raises FY2026 Sales Guidance from $2.740B-$2.820B to $2.850B-$2.910B vs $2.797B Est
Natera (NASDAQ: NTRA ) raises FY2026 sales outlook from $2.740 billion-$2.820 billion to $2.850 billion-$2.910 billion vs $2.797 billion estimate.
EARNINGS | Aug 06, 2026, 08:17 PM UTC
M
Japan: Natera Submits Signatera For Approval
Natera submits Signatera for approval in Japan
EQUITY | Aug 05, 2026, 10:03 AM UTC
L
NTRA - Natera to Report its Second Quarter Results on August 6, 2026
NTRA - Natera to Report its Second Quarter Results on August 6, 2026
EARNINGS | Jul 30, 2026, 12:03 PM UTC
L
GH NTRA expert sees coverage tailwinds @ RBC
GH NTRA expert sees coverage tailwinds @ RBC
EQUITY | Jul 28, 2026, 11:09 AM UTC
L
NTRA Natera's Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
NTRA Natera's Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
EQUITY | Jul 22, 2026, 10:38 AM UTC
L
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
On Monday, Tempus AI, Inc. (NASDAQ: TEM ) agreed to acquire Personalis, Inc. (NASDAQ: PSNL ), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities. Tempus AI shares erased earl
RATES | Jul 21, 2026, 06:52 PM UTC
H
Natera price target raised to $310 from $250 at Morgan Stanley
Morgan Stanley raised the firm's price target on Natera to $310 from $250 and keeps an Overweight rating on the shares. The firm is updating its model ahead of the earnings report.
EARNINGS | Jul 09, 2026, 10:59 AM UTC
L
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
EQUITY | Jul 06, 2026, 10:00 AM UTC
M
NTRA: Barclays Maintains Overweight
Barclays maintains overweight rating on Natera, lowers price target to $260
EQUITY | Jun 24, 2026, 02:55 PM UTC
M
NTRA Gets Japan Approval
NTRA's Signatera receives regulatory approval in Japan for colorectal cancer
EQUITY | Jun 24, 2026, 09:15 AM UTC
M
NTRA Wins Japan Approval
Natera's Signatera wins regulatory approval in Japan for colorectal cancer, with a commercial launch expected by year-end 2026
EQUITY | Jun 24, 2026, 07:52 AM UTC
M
NTRA: BTIG Raises PT
BTIG maintains buy rating on Natera and raises price target to $270
EQUITY | Jun 23, 2026, 08:05 PM UTC
M
NTRA Added to NCCN Guidelines
Natera's Signatera test is added to NCCN bladder cancer guidelines, strengthening its support in bladder cancer care
EQUITY | Jun 23, 2026, 10:06 AM UTC